Trimethaphan Camphorsulfonate in the Treatment of Shock.
- Author:
Kunil LEE
1
Author Information
- Publication Type:Case Report
- MeSH: Cause of Death; Central Venous Pressure; Humans; Hypotension; Hypovolemia; Infusions, Intravenous; Oxygen; Plasma; Respiration; Shock*; Trimethaphan*; Vasoconstriction; Vasodilation
- From:Korean Journal of Anesthesiology 1969;2(1):35-39
- CountryRepublic of Korea
- Language:Korean
- Abstract: Trimethaphan camphorsulfonate (Arfonad), in 0.1 per cent concentration, has been administered slowly by intravenous drip to 6 patients in shock and protracted vasoconstrictive states. Administration of Arfonad results in vasodilation and relative hypovolemia. Blood or plasma expander was required to avoid an unacceptable hypotension. All patients survived except one, in whom the cause of death was not related .in any way to the use of Arfonad. Importance of supplementing respiration with oxygen and monitoring central venous pressure has been stressed and the rational use of both vasoconstrictor and vasiodiator discussed. At times, vasodilation is desirable, at other times, it may best be avoided. It is suggested that Arfonad may have a place in the treatment of shock but if so, it should be used only when protracted vasoconstriction exists.
